Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR®, ArmoredCAR®, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan
View Top Employees from Innovative Cellular Therapeutics (ICT)Website | http://www.ictbio.com |
Revenue | $6 million |
Funding | $28.6 million |
Employees | 14 (13 on RocketReach) |
Founded | 2009 |
Address | 1405 Research Blvd, Rockville, Maryland 20850, US |
Phone | (240) 690-9110 |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Innovative Cellular Therapeutics (ICT) employee's phone or email?
The Innovative Cellular Therapeutics (ICT) annual revenue was $6 million in 2024.
Xiaobin Lu is the CTO of Innovative Cellular Therapeutics (ICT).
13 people are employed at Innovative Cellular Therapeutics (ICT).
Innovative Cellular Therapeutics (ICT) is based in Rockville, Maryland.
The NAICS codes for Innovative Cellular Therapeutics (ICT) are [32, 325, 3254].
The SIC codes for Innovative Cellular Therapeutics (ICT) are [80, 283, 28].